FOLH1 and posterior cortical atrophy: These advancements underscore PSMA’s potential in future precision medicine applications, such as FGS and localized photothermal (PTT) therapy or photodynamic therapy (PDT), solidifying its role in the next generation of PCa management strategies (Figure 1).